Authors


Jennifer Christian, PharmD, PhD

Latest:

Using Real-World Data to Examine Long-Term Safety and Effectiveness in Extension Studies

Leveraging RWD can lessen the strain normally put on investigators and sites.


Ethan Davidoff

Latest:

Making Medication Assistance Program Solutions Work for You

How technology can maximize use of manufacturer copay and patient assistance programs.


Kevin Cast

Latest:

Navigating the Future: Key Market Access Trends to Watch in ’24

Five emerging themes likely to impact pharma in the new year.


Chris Smyth

Latest:

Capitalizing On Collaboration and Confidence: Survey Insights and Expectations For Biotech in 2024

Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.


Syft Technologies

Latest:

Real-Time Measurement of EPA Regulated HON Compounds and Environmental Pollutants Using SIFT-MS

This application note summarizes key SIFT-MS results presented in a peer reviewed article entitled “Unreported VOC Emissions from Road Transport Including from Electric Vehicles.” Learn how the Wolfson Atmospheric Chemistry Laboratory at the University of York used SIFT-MS for VOC analysis in its platform to experimentally verify that motor vehicle screen wash is a significant unreported source of VOC emissions (especially for ethanol and methanol).


Laura Child

Latest:

New Horizons for Patient-Centric Drug Delivery

Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.


Adam Lohr

Latest:

Biopharma and ESG: Key Strategies for Companies, Meaningful Changes to Communities

New regulations set stage for updated ESG considerations.


Chris Martin

Latest:

Lessons Learned on the Art and Science of Product Commercialization

Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.



Naveen Murthy

Latest:

Investing for Success: Finding the Right Launch Balance

Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.



Simon Bates and Valerie Phillips

Latest:

2021 Projections on the Future of Patient Engagement in Pharma

On the back of COVID-19, pharma has an opportunity to radically rethink a long-held reluctance to build end-customer relationships into their core business models, writes Simon Bates and Valerie Phillips.


Nicholas Stailey

Latest:

Commercial Sustainability of Pharmaceutical Innovations for Pandemics

Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.


Nitin Riyal

Latest:

Developing a Product Launch Strategy for an Orphan Drug

Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.



Robin Wechkin, Sara B. Brody, Sarah Hemmendinger

Latest:

Securities Litigation Arising from Alzheimer's Drug Treatments

The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.


Ken McLaren

Latest:

How AI is Revamping the Product Launch

New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.


Eva Mitchell

Latest:

Rx Power Struggle: How Pharma can Flip the PBM Script

The industry holds the key to true change to the drug access landscape.


Ryan Murphy

Latest:

Validating COAs: Key Steps for Accurate and Reliable Clinical Trial Data

With the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.


Deepak Sirdeshmukh, MS, PhD

Latest:

How Technology Can be Used to Improve Adherence

Comprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.


Ronan Brown, PhD

Latest:

Turning COVID-19 Era Regulatory Efficiencies into Long-term Business Growth and Innovation

COVID-19 pandemic sets new standards for life sciences industry.




Menassie Taddese

Latest:

The Interplay Between COVID-19 Pandemic and NCD Epidemic

Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.


Thom Stambaugh, RPh

Latest:

Combating the Opioid Crisis With Long-Acting Injectables

Substance use disorder is a complex condition that demands innovative solutions, one of which that has shown promise is the use of long-acting injectables.


Scott Coons

Latest:

Investing for Success: Finding the Right Launch Balance

Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.



Martin Slusarczyk, PhD

Latest:

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.


Srikant Vaidyanathan

Latest:

Clues on Equity Engagement Levels

A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.


Peter Malamis, MBA

Latest:

Data Intermediaries/Software Can Speed the Usage of Real-World Data

Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.